

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/567,146	07/18/2006	John Francis Hoke	PB60428	9414
20462 7590 07/13/2010 GlaxoSmithKline		EXAMINER		
GLOBAL PATENTS -US, UW2220			WESTERBERG, NISSA M	
P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939			ART UNIT	PAPER NUMBER
III.O OI III.	3,0011,11115 100 0525		1618	
			NOTIFICATION DATE	DELIVERY MODE
			07/13/2010	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US\_cipkop@gsk.com

## Application No. Applicant(s) 10/567.146 HOKE ET AL. Notice of Abandonment Examiner Art Unit Nissa M. Westerberg 1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address-

This application is abandoned in view of:
<ol> <li>Applicant's failure to timely file a proper reply to the Office letter mailed on <u>07 December 2009</u>.</li> <li>A reply was received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply (including a total extension of time of</li></ol>
(b) A proposed reply was received on, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection
(A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).
(c) ☐ A reply was received on but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
(d) ⊠ No reply has been received.
<ol> <li>Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three month from the mailing date of the Notice of Allowance (PTOL-85).</li> </ol>
(a) The issue fee and publication fee, if applicable, was received on(with a Certificate of Mailing or Transmission date), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice Allowance (PTOL-85).
(b) ☐ The submitted fee of \$ is insufficient. A balance of \$ is due.
The issue fee required by 37 CFR 1.18 is \$ The publication fee, if required by 37 CFR 1.18(d), is \$
(c) The issue fee and publication fee, if applicable, has not been received.
3. Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).
(a) ☐ Proposed corrected drawings were received on(with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply.
(b) No corrected drawings have been received.
1. The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.
<ol> <li>The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.</li> </ol>
6. The decision by the Board of Patent Appeals and Interference rendered on and because the period for seeking court revie of the decision has expired and there are no allowed claims.
7. ☐ The reason(s) below:
The abandonment was confirmed by Kathryn Sieburth on June 22, 2010
/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618
Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to

minimize any negative effects on patent term.

U.S. Patent and Trademark Office
PTOL-1432 (Rev. 04-01)